|
|
Volumn 18, Issue 4, 2012, Pages 474-
|
|
Companies hope for rare win with cancer stem cell therapies
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
SUNITINIB;
ANTIANGIOGENIC ACTIVITY;
CANCER STEM CELL;
CANCER THERAPY;
CELL DIFFERENTIATION;
CELL POPULATION;
CELL THERAPY;
CLINICAL EFFECTIVENESS;
DRUG DEVELOPMENT;
DRUG INDUSTRY;
HUMAN;
MOLECULARLY TARGETED THERAPY;
NOTE;
PATIENT SAFETY;
PHASE 1 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROCESS DEVELOPMENT;
SIGNAL TRANSDUCTION;
ANTINEOPLASTIC AGENTS;
DENDRITIC CELLS;
DRUG INDUSTRY;
HUMANS;
NEOPLASMS;
NEOPLASTIC STEM CELLS;
TECHNOLOGY, PHARMACEUTICAL;
|
|
EID: 84859564011
PISSN: 10788956
EISSN: 1546170X
Source Type: Journal
DOI: 10.1038/nm0412-474a Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|
